Medidata Validates Oncology Trial Optimization and CAR T Efficacy at ASCO 2026 — Medidata Solutions, Inc.

Event summary

Medidata will present two research abstracts at ASCO 2026, focusing on oncology protocol optimization and CAR T efficacy.
Protocol optimization research identified a 10-23% reduction in enrollment rates with PET imaging and up to 10% reduction in dropout rates with blood cell analyses.
CAR T efficacy study found 66% of patients achieved complete response with tocilizumab treatment for CRS.
Research leverages Medidata’s AI-powered Protocol Optimization and the Medidata Research Alliance.

The big picture

Medidata’s research at ASCO 2026 underscores the growing importance of AI and data analytics in optimizing clinical trials, particularly in complex oncology studies. The findings on protocol design and CAR T efficacy highlight the strategic shift towards patient-centric trial execution, which is critical as the industry faces increasing pressure to accelerate drug development. With over 38,000 trials supported, Medidata’s insights could reshape how sponsors approach trial design and patient engagement.

What we're watching

Protocol Optimization: How Medidata’s AI-driven protocol optimization will impact future oncology trial designs and patient recruitment strategies.
CAR T Therapies: Whether the validated efficacy of tocilizumab for CAR T-induced CRS will accelerate adoption in clinical practice.
Data Collaboration: The pace at which Medidata’s Research Alliance can drive additional breakthroughs through cross-industry data sharing.